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Abstract
AIM
To investigate whether glucagon-like peptide-2 (GLP-2) 
influences the neurally-induced responses in gastric 
strips from mice, since no data are available. 
METHODS
For functional experiments, gastric fundal strips were 
mounted in organ baths containing Krebs-Henseleit 
solution. Mechanical responses were recorded via  force-
displacement transducers, which were coupled to a 
polygraph for continuous recording of isometric tension. 
Electrical field stimulation (EFS) was applied via two 
platinum wire rings through which the preparation 
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was threaded. The effects of GLP-2 (2 and 20 nmol/L) 
were evaluated on the neurally-induced contractile 
and relaxant responses elicited by EFS. Neuronal nitric 
oxide synthase (nNOS) enzyme was evaluated by 
immunohistochemistry.
RESULTS
In the functional experiments, electrical field sti-
mulation (EFS, 4-16 Hz) induced tetrodotoxin (TTX)-
sensitive contractile responses, which were reduced 
in amplitude by GLP-2 (P  < 0.05). In the presence of 
the nitric oxide (NO) synthesis inhibitor L-NNA, GLP-2 
no longer influenced the neurally-evoked contractile 
responses (P  > 0.05). The direct smooth muscle 
response to methacholine was not influenced by 
GLP-2 (P  > 0.05). In the presence of guanethidine 
and carbachol, the addition of GLP-2 to the bath 
medium evoked TTX-sensitive relaxant responses that 
were unaffected by L-NNA (P  > 0.05). EFS induced a 
fast NO-mediated relaxation, whose amplitude was 
enhanced in the presence of the hormone (P  < 0.05). 
Immunohistochemical experiments showed a significant 
increase (P  < 0.05) in nNOS immunoreactivity in the 
nerve structures after GLP-2 exposure. 
CONCLUSION
The results demonstrate that in gastric fundal strips, 
GLP-2 influences the amplitude of neurally-induced 
responses through the modulation of the nitrergic 
neurotransmission and increases nNOS expression. 
Key words:  Immunohistochemistry; Gastric motility; 
Glucagon-like peptide-2; Neuronal nitric oxide synthase; 
Non-adrenergic non-cholinergic neurotransmission
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip:The results of the present study demonstrate 
for the first time that, in strips from the mouse gastric 
fundus, glucagon-like peptide-2 (GLP-2) depresses 
the amplitude of the neurally-induced contractile 
responses and enhances the amplitude of the 
relaxant ones through the modulation of the nitrergic 
neurotransmission. GLP-2 also increases neuronal 
nitric oxide synthase immunoreactivity in the nerve 
structures. All these inhibitory effects might contribute 
to gastric relaxation, thus increasing the organ capacity. 
Since gastric distension represents a peripheral satiety 
signal from a physiological point of view, it could be 
speculated that the relaxant effects of GLP-2 might 
concur to suppress feeding behavior in rodents. 
Garella R, Idrizaj E, Traini C, Squecco R, Vannucchi MG, 
Baccari MC. Glucagon-like peptide-2 modulates the nitrergic 
neurotransmission in strips from the mouse gastric fundus. World 
J Gastroenterol 2017; 23(40): 7211-7220  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v23/i40/7211.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v23.i40.7211
INTRODUCTION
Glucagon-like peptide-2 (GLP-2), produced by 
enteroendocrine “L” cells[1,2], plays a role in the 
regulation of metabolism and energy homeostasis[3,4], 
and has been reported to influence many gastro-
intestinal functions[5,6]. GLP-2 acts on G protein-
coupled receptors (GLP-2r)[7-9] largely distributed in the 
gastrointestinal tract[2,10]. In the gut, GLP-2r has been 
revealed in several cell types, including excitatory and 
inhibitory neurons[10-13]. In this view, GLP-2 has been 
demonstrated to exert a neuromodulatory action either 
by inhibiting intestinal transit in vivo[14] or by reducing 
colonic and duodenal cholinergic muscle contractions 
in vitro[10,11]. 
Concerning gastric motility, contrasting results have 
been reported in humans regarding the ability of GLP-2 
to slow emptying[15-17]. In vivo experiments in pigs 
have shown that the hormone reduced antral motility 
through central nervous system mechanisms[18]. In 
addition to the central actions, experiments carried out 
in vitro have demonstrated that GLP-2 exerts peripheral 
effects on either gastric strips or isolated whole stomach 
from mice[19]. Particularly, the hormone has been shown 
to relax gastric smooth muscle acting indirectly through 
the stimulation of vasoactive intestinal polypeptide 
(VIP) release from myenteric neurons with site-related 
effects, exerting its action in the fundal region only[19]. 
However, to our knowledge, no data have been reported 
about the influence of GLP-2 on the neurally-induced 
gastric responses elicited by electrical stimulation in in 
vitro preparations. For the above reason, we presently 
investigated whether GLP-2 influences the neurally-
induced contractile and relaxant responses in gastric 
fundal strips from mice. Along with VIP[20], nitric oxide 
(NO)[21] is considered one of the major non-adrenergic, 
non-cholinergic (NANC) inhibitory neurotransmitters 
responsible for the proximal stomach relaxation; thus, 
we also evaluated the effects of GLP-2 on both the 
nitrergic neurotransmission and the neuronal nitric 
oxide (nNOS) expression.
MATERIALS AND METHODS
Animals
Experiments were performed on 8- to 12-week-
old female mice (CD1 Swiss strain; Envigo, Udine, 
Italy). The animals were kept under the following 
conditions: 12-h light/12-h dark photoperiod, constant 
temperature (21 ± 1 ℃), and standard laboratory 
feed. The mice were killed by prompt cervical 
dislocation to minimize animal suffering. 
Mechanical experiments
As formerly reported[22-25], the stomach was promptly 
removed, and two full-thickness longitudinal strips 
(2 mm × 10 mm) were cut from each gastric fundal 
region. One end of each strip was tied to a platinum 
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rod, while the other was connected to a force dis-
placement transducer (Grass model FT03, Quincy, 
MA, United States) by a silk thread for continuous 
recording of isometric tension. The transducer was 
coupled to a polygraph (Grass model 7K, Quincy, 
MA, United States). Preparations were mounted in 
double-jacketed organ baths (5 mL) containing Krebs-
Henseleit solution, gassed with a 95% O2-5% CO2 
mixture, of the following composition (mmol/l): NaCl 
118, KCl 4.7, MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, 
CaCl2 2.5 and glucose 10 (pH 7.4). The temperature 
of the Krebs-Henseleit solution in the organ baths was 
maintained at 37 ± 0.5 ℃.
Electrical field stimulation (EFS) was applied by 
means of two platinum wire rings (2 mm diameter, 
5 mm apart) through which the strip was threaded. 
Electrical pulses (rectangular waves, 80 V, 4-16 Hz, 
0.5 ms, for 15 s) were delivered by a Grass model S8 
stimulator. Preparations were allowed to equilibrate for 
1 h under an initial load of 0.8 g: during this period, 
prolonged washes with Krebs-Henseleit solution were 
performed to avoid the accumulation of metabolites in 
the organ baths. 
Experimental protocol
The influence of GLP-2 (2 nmol/L and 20 nmol/L) 
on either neurally-induced or direct smooth muscle 
contractile responses was firstly investigated. EFS 
(4-16Hz) was also performed in the presence of 1 
μmol/L tetrodotoxin (TTX) or 200 μmol/L NG-nitro-
l-arginine (L-NNA). Elapsed time between two 
subsequent electrical stimulations depended on the 
time taken by the strip tension to regain baseline. 
The interval between two subsequent direct muscular 
responses to methacholine (2 μmol/L) was at least 
30 min. During this period prolonged washes with 
Krebs-Henseleit solution were performed. To verify the 
viability of the strips, contractions to methacholine (2 
μmol/L) were evaluated at the beginning and at the 
end of each experiment.
In a second series of experiments, the effects of 
GLP-2 (2 nmol/L and 20 nmol/L) on the EFS-induced 
NANC relaxant responses were investigated. For this 
purpose, functional experiments were carried out 
in the presence of 1 μmol/L guanethidine sulphate 
and 1 μmol/L carbachol (CCh) to rule out adrenergic 
and cholinergic influences, respectively. Elapsed time 
between two subsequent additions of CCh was at 
least 15 min, during which prolonged washes with 
Krebs-Henseleit solution were performed. When a 
stable plateau phase of the contraction evoked by 
CCh was reached, EFS or drugs were applied. The 
response to GLP-2 (2 nmol/L and 20 nmol/L) was 
also tested 20 min following the addition of TTX or 
the NO synthesis inhibitor l-NNA to the bath medium. 
Immunohistochemical experiments were performed in 
parallel. 
Tissue sampling for morphological studies 
Two gastric fundus specimens per animal (6 mice) 
were taken, which were prepared as reported above 
and handled as follows. The specimens were stabilized 
in 5 mL organ baths containing Krebs-Henseleit 
solution; at the end of the steadying period, one half 
of the specimens was exposed to GLP-2 for 30 min, 
which was added directly to the bath reaching 20 
nmol/L concentration. The second half was maintained 
in Krebs solution and used as a control. At the end of 
the exposure time, the specimens were transferred 
into a solution of paraformaldehyde (4%) dissolved in 
phosphate-buffered saline (0.1 mol/L, PBS, pH 7.4), 
maintained overnight (ON) at 4 ℃. The day after, the 
specimens were dehydrated, cleared in xylene and 
embedded in paraffin. The rotary microtome (MR2, 
Boeckeler Instruments Inc. Tucson, Arizona, United 
States) allowed to cut 5 μm thick sections, which 
were collected on slides suitable to histological and 
immunofluorescent staining.   
Histological and immunofluorescent staining
The sections were deparaffinized through consecutive 
passages in xylene and in decreasing ethanol 
concentration solutions up to the final step in distilled 
water. Some sections were H&E stained to visualize 
the integrity of the muscle wall. Some others 
underwent the immunofluorescent procedure. For 
antigen retrieval the sections were transferred for 
20 min in a EDTA 1 mmol/L, pH 9.0 + tris buffer 10 
mmol/L, maintained at the temperature of 90-92 ℃; 
then they were allowed to cool in the same solution. 
After few washes in 0.1 mol/L PBS, the section were 
first incubated for 20 min with bovine serum albumin 
(1.5%, Sigma Aldrich, Milan, Italy) diluted in PBS and 
then ON at 4 ℃ in the presence of the nNOS antibody 
(rabbit polyclonal; 1:1500; Chemicon, Temecula, CA, 
United States). After several washes, the appropriate 
fluorochrome-conjugated secondary antibody 
(goat anti-rabbit, AlexaFluor 488; 1:333; Jackson 
ImmunoResearch, West Grove, PA, United States) 
diluted in PBS were applied for 2 h at RT. Finally, 
the sections were counterstained with Bisbenzimide 
Hoechst Trihydrochloride (BHT; Sigma Aldrich srl, 
Milan, Italy) to visualize the cell nuclei, and set in the 
aqueous medium (Immu-Mount, Thermo Scientific, 
Waltham, MA, United States).  To verify the specificity 
of the primary antibody, the procedure has been 
performed omitting the antibody. An epifluorescence 
microscope (Zeiss Axioskop microscope, Oberkochen, 
Germany) allowed to visualize the fluorescent labelling. 
A digital camera (Leica DFC310 FX 1.4-megapixel 
camera, Leica Microsystems, Mannheim, Germany) 
coupled to an image acquisition software (LAS V3.8, 
Leica Microsystems, Germany) allowed to capture and 
archive the related images. 
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RESULTS
Functional experiments
At basal tension (n = 28), EFS (4-16 Hz) induced 
contractile responses whose amplitude increased by 
increasing the stimulation frequency (Figure 1A and 
B). These responses were abolished by 1 μmol/L TTX 
(n = 4) indicating their nervous nature. The addition 
of GLP-2 (2 nmol/L or 20 nmol/L) to the bath medium 
(n = 16), other than causing a long-lasting decay of 
the basal tension (0.15 ± 0.02 and 0.20 ± 0.03 g at 
2 nmol/L and 20 nmol/L, respectively), decreased the 
amplitude of the excitatory responses elicited by EFS 
(Figure 1A and B). 
In the presence of the NO synthesis inhibitor 
L-NNA (200 μmol/L) the amplitude of the EFS-induced 
contractions was enhanced (Figure 2A and B). The 
effects of l-NNA, already appreciable 10 min after its 
addition to the bath medium, persisted up to 1 h (longer 
time not observed). In the presence of L-NNA (200 
μmol/L), GLP-2 (2 nmol/L or 20 nmol/L) still evoked 
the decay of the basal tension (Figure 2A and B) but 
no longer depressed the amplitude of the EFS-induced 
contractile responses even at the highest concentration 
employed (Figure 2A and B). 
Methacholine (2 μmol/L) caused a sustained 
contraction that was TTX-insensitive and reached a 
plateau phase (mean amplitude 0.98 ± 0.3 g) that 
persisted until washout. GLP-2 (2 nmol/L or 20 nmol/L) 
did not influence the response to methacholine (mean 
amplitude 1.02 ± 0.2 g, P > 0.05). No significant 
differences (P > 0.05) in amplitude of the contractile 
response to methacholine (2 μmol/L) were observed 
between that obtained at the end or at the beginning 
of the experiments, thus indicating that the viability of 
the preparations was not compromised.
The effects of GLP-2 were also tested on the 
neurally-induced relaxant responses. In the presence 
of guanethidine, addition of CCh (1 μmol/L) to the bath 
medium (n = 28) caused a rapidly arising contraction 
(mean amplitude 1.2 ± 0.2 g), which persisted until 
washout. In CCh precontracted strips, GLP-2 (2 nmol/L 
or 20 nmol/L) elicited (n = 12) dose-dependent slow 
and long-lasting relaxations (Figure 3) that were 
abolished by 1 μmol/L TTX (n = 4; data not shown) 
and unaffected (P > 0.05) by L-NNA (200 μmol/L) (n 
= 4) (mean amplitude 27 ± 1.5% vs 25 ± 1.9% and 
47 ± 1.7% vs 50 ± 1.6% at 2 nmol/L and 20 nmol/L, 
respectively). 
In CCh precontracted strips, EFS (4-16 Hz) elicited 
(n = 16) a fast relaxant response followed, at the 
higher stimulation frequencies, by a slow relaxation 
(Figure 4A). As previously observed in the mouse 
gastric fundus[23], the fast component of the response 
was abolished by 200 μmol/L L-NNA (n = 4), indicating 
its nitrergic nature. In the presence of GLP-2 (2 nmol/L 
or 20 nmol/L), the amplitude of the EFS-induced fast 
nitrergic relaxation was increased (P < 0.05; Figure 
Quantitative analysis 
The quantitative analysis of the labelled structures was 
done acquiring digitized images for the whole length 
of the section (1 section/animal; 6 animals/group) 
using 20 x objective and the acquisition of overlapping 
images was avoided. The total number of images 
obtained was comparable between control and GLP-2 
treated sections as confirmed by the similar length of 
the fundal specimens. ImageJ (NIH, Bethesda, MD, 
United States) was used to analyze the fluorescent 
labeling in the acquired images. The area of the 
labelled structures in the muscle wall was quantified 
and expressed as fraction of the total image area x 
100. The labelling was converted to a binary image; 
the threshold value was set in control images and 
maintained in treated ones. Two researchers counted 
in blind the myenteric labelled neurons in each section 
(1 section/mouse; 6 mice/group) and the result was 
proposed as neuron number per mm.  
Drugs
The following drugs were used: guanethidine sulphate, 
CCh, GLP-2, methacholine, L-NNA, TTX. All of the 
above drugs were purchased from Sigma Chemical 
(St. Louis, MO, United States) with the exception of 
GLP-2 that was obtained from Tocris Bioscience (Bristol, 
United Kingdom). Solutions were freshly prepared, 
except for TTX, for which a stock solution was stored 
at -20 ℃. Drug concentrations are referred as final 
bath concentrations and are in the range of those 
previously reported to be effective in in vitro gastric 
preparations[26-28]. Particularly, the chosen doses of 
GLP-2 employed are those reported able to cause 
gastric relaxation in mice[19].  
Data analysis and statistical tests 
Amplitude of contractions is given as percentage of 
the muscular contraction elicited by methacholine (2 
μmol/L) taken as 100% or as absolute values (g). 
Amplitude of responses to methacholine was measured 
30 s after a stable plateau phase was reached. 
Relaxant responses are calculated as percentage 
decrease relative to the muscular tension induced by 
CCh (1 μmol/L) just before obtaining relaxations. With 
respect to pre-stimulus level, amplitude values of EFS-
induced fast relaxations refer to the maximal peak 
obtained during the stimulation period and amplitude 
values of EFS-induced sustained relaxations refer to 
the maximal peak, obtained following the stimulation 
period. The statistical significance was evaluated by 
paired or unpaired Student t-test to compare two 
experimental groups or one-way ANOVA followed by 
Newman-Keuls posttest when more than two groups 
were compared (Prism 3.0; GraphPad Software, San 
Diego, CA, United States). Differences were considered 
significant when P ≤ 0.05. Results are mean ± SE. 
The number of muscle strip preparations is indicated 
by n in the results. 
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4A and B), whereas that of the slow relaxation was 
reduced (6.1 ± 0.6% vs 12.75 ± 2.3% and 19.68 ± 
1.6% vs 30.46 ± 2.2%, at 8 and 16 Hz, respectively; 
P < 0.05) (Figure 4A) or even abolished at the highest 
dose employed.
Morphological experiments
Anatomical and histological evaluation: At the 
end of the tissue sampling procedure, the control and 
GLP-2 treated specimens appeared anatomically intact 
and the H&E staining confirmed the integrity of the 
muscle wall (Figure 5). 
Immunofluorescence: In the gastric fundus of both 
control (Figure 6A-C) and GLP-2 (20 nmol/L) treated 
specimens (Figure 6D-F), the nNOS-immunoreactivity 
(IR) was observed in the soma of the myenteric 
neurons and in the fibers located in the longitudinal 
and circular muscle layers. No IR was detected when 
the primary antibody was omitted (Figure 6G-H). 
Quantitation of the IR showed a statistically significant 
increase in nNOS positive neuron number and nerve 
fibers (Figure 6I). The length of gastric fundal strips 
subjected to quantitative analysis was not different 
between control and GLP-2 treated specimens (4.17 ± 
0.60 mm controls vs 4.07 ± 0.48 mm GLP-2 treated).
DISCUSSION
The present study demonstrates for the first time that 
GLP-2 influences the neurally-induced contractile and 
relaxant responses in mouse fundal strips through a 
modulatory action on nitrergic neurotransmission and 
increases nNOS expression. Particularly, the functional 
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Figure 1  Influence of glucagon-like peptide-2 on the neurally-induced contractile responses. A: Typical tracing showing the electrical field stimulation (EFS)-
induced contractile responses at different stimulation frequencies (left panel). Ten min after the addition of 2 nmol/L glucagon-like peptide-2 (GLP-2) to the bath 
medium (right panel), the amplitude of the EFS-induced excitatory responses is decreased in the whole range of stimulation frequencies employed; B: Bar chart of the 
effects of GLP-2 (2 and 20 nmol/L) on the mean amplitude of the EFS-induced contractile responses elicited at different stimulation frequencies. Excitatory responses 
are expressed as percentage of the muscular contraction evoked by 2 μmol/L methacholine, taken as 100%. All values are mean ± SE of six preparations. aP < 0.05 
vs the ctr bP < 0.05 and P > 0.05 vs the ctr and vs 2 nmol/L GLP-2, respectively, ANOVA and Newman-Keuls post-test).
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Figure 2  Lack of effects of glucagon-like peptide-2 on the neurally-induced contractile responses in the presence of the nitric oxide synthesis inhibitor 
L-NNA. A: Typical tracing showing the electrical field stimulation (EFS)-induced contractile responses at different stimulation frequencies (left panel). Following the 
addition of L-NNA (200 µmol/L) to the bath medium, the amplitude of the EFS-induced excitatory responses is enhanced (middle panel). In the presence of L-NNA, 
glucagon-like peptide-2 (GLP-2, 20 nmol/L) no longer depresses the amplitude of the neurally-induced contractile responses (right panel); B: Bar chart of the effects of 
GLP-2 (20 nmol/L) on the mean amplitude of the EFS-induced contractile responses in the presence of L-NNA (200 µmol/L). Excitatory responses are expressed as 
percentage of the muscular contraction evoked by 2 μmol/L methacholine, taken as 100%. All values are mean ± SE of six preparations. aP < 0.05 vs the ctr bP < 0.05 
and P > 0.05 vs the ctr and vs GLP-2, respectively (ANOVA and Newman-Keuls post-test).
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experiments show that GLP-2 is able to depress the 
amplitude of the EFS-induced contractile responses at 
each stimulation frequency applied.
It is known that gastric motor responses are a 
balance between nervous excitatory (mainly cholinergic) 
and inhibitory (NANC) influences exerted on the 
smooth muscle.  Since during EFS both excitatory and 
inhibitory nervous fibers are simultaneously activated, 
the reduction in amplitude of the neurally-induced 
contractions caused by GLP-2 might be ascribable either 
to a minor activation of the excitatory component or 
to a major nervous inhibitory influence exerted on the 
smooth muscle. In this view, the increase in amplitude 
of the EFS-induced contractile responses by the NO 
synthesis inhibitor L-NNA indicates the removal of 
a nitrergic inhibitory nervous influence. Notably, in 
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CCh 1 μmol/L
GLP-2 2 nmol/L
CCh 1 μmol/L
GLP-2 20 nmol/L
Figure 3  Effects of glucagon-like peptide-2 on gastric strips precontracted with carbachol. Typical tracings showing the effect of the addition of glucagon-
like peptide-2 (GLP-2, 2 and 20 nmol/L) to the bath medium. GLP-2 causes a dose-dependent slow and long-lasting relaxation. CCh: Carbachol .
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Figure 4  Influence of glucagon-like peptide-2 on the neurally-induced relaxant responses. A: Typical tracing showing the electrical field stimulation (EFS)-induced 
relaxant responses at different stimulation frequencies (left panel). EFS evokes fast relaxant responses, followed by a slow component at the higher stimulation 
frequencies (≥ 8 Hz). GLP-2 at 2 nmol/L causes (right panel) an increase in amplitude of the EFS-induced fast relaxation in whole range of stimulation frequencies 
employed and a decrease of the slow one; B: Bar chart of the effects of GLP-2 (glucagon-like peptide-2, 2 and 20 nmol/L) on the mean amplitude of the EFS-induced 
fast relaxation. Note that GLP-2 increases the amplitude of the EFS-induced fast relaxant responses in a dose-related manner. Relaxant responses are expressed as 
percentage decrease relative to the muscular tension induced by 1 μmol/L CCh taken as 100%. Amplitude values of EFS-induced fast relaxations refer to the maximal 
peak obtained during the stimulation period. All values are mean ± SE of six preparations. aP < 0.05 vs the ctr; cP < 0.05 vs the ctr and vs 2 nmol/L GLP-2 (ANOVA 
and Newman-Keuls post-test).
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the presence of L-NNA, GLP-2 no longer depressed 
the amplitude of the neurally-induced excitatory 
responses. These data demonstrate that the hormone 
effects on the EFS-induced contractions occur through 
the modulation of the nitrergic neurotransmission 
and, in addition, exclude its inhibitory action on the 
cholinergic neurotransmission.  
The lack of effects of GLP-2 on the direct smooth 
muscle responses elicited by methacholine further 
supports its neuromodulatory action. This observation 
also proves that the depressant actions of GLP-2 
on the EFS-induced contractile responses are not 
ascribable to aspecific effects such as the decay of the 
basal tension. Moreover, the similar amplitude of the 
contraction to methacholine at the beginning and at 
the end of the experiments demonstrates that muscle 
responsiveness is not compromised. 
In keeping with the above observations, the 
results of the experiments performed in the presence 
of guanethidine and CCh demonstrate, for the first 
time, that the hormone influences the amplitude of 
the neurally-induced relaxant responses in gastric 
fundal strips through a modulatory action on the 
nitrergic neurotransmission. As previously observed in 
strips from the mouse gastric fundus in the presence 
of guanethidine and CCh[23,26,28], EFS induced a fast 
NO-mediated relaxation, followed by a slow and 
sustained relaxant response at the highest stimulation 
frequencies. In the present experiments, the 
observation that GLP-2 increased the amplitude of the 
EFS-induced fast nitrergic relaxation in the whole range 
of stimulation frequencies in a dose-related manner 
further supports the involvement of the NO pathway in 
the hormone effects. To ascertain whether the effects 
of GLP-2 on both the neurally-induced contractile and 
relaxant responses were ascribable to an increased NO 
production, nNOS expression was evaluated in gastric 
preparations by immunohistochemistry. The results 
show that GLP-2 induces an increase in the nNOS 
labeling in the nerve structures of the gastric fundus 
muscle coat. Accordingly, an increased NO production 
in neurons induced by exogenous GLP-2 has been 
suggested to occur in the mouse duodenum in which 
the hormone inhibited the spontaneous mechanical 
activity[11]. In the present experiments, the increased 
nNOS expression in the nerve structures of the 
muscle wall fits well with the progressive decrease in 
amplitude of the EFS-induced contractile responses as 
well as with the increase of the fast relaxant responses 
caused by GLP-2. Thus, these hormone effects occur 
only during EFS, i.e., when the nitrergic pathway is 
engaged, also explaining the ineffectiveness of L-NNA 
to influence the relaxant response induced by the 
addition of GLP-2 to bath medium. Indeed, gastric 
relaxation to GLP-2 in mice has been reported to occur 
through the release of VIP from myenteric neurons[19]. 
In this view, immunohistochemical studies in mouse, 
human and porcine intestine reported the presence of 
the GLP-2 receptor in the enteric neurons[10-12,29] and 
showed that some of them co-localized with VIP[11,12]. 
We previously observed[26] that, in strips from the 
mouse gastric fundus, the EFS-induced slow relaxation 
was abolished following VIP receptors desensitization, 
suggesting the involvement of the peptide in this 
kind of response. On this basis, it could be speculated 
that the reduction/abolition of the neurally-induced 
slow relaxation by GLP-2 observed in the present 
experiments occurred because VIP, released earlier 
from the nerve terminal by the hormone, has already 
occupied the muscular receptors engaged in the EFS-
induced vipergic relaxant response. However, even 
if the validation of this hypothesis was beyond the 
aim of the present work, the observation that GLP-2 
influences in an opposite manner the two components 
of the neurally-induced relaxant responses excludes an 
aspecific effect. 
The present results demonstrate that the hormone 
depresses the amplitude of the neurally-induced 
mp cml
lml
mp
cml
lml
Ctrl                                                                                                          GLP-2
A B
Figure 5  H&E staining of gastric fundus strip. The longitudinal and circular muscle layers (lml, cml) and the myenteric plexus (mp) are shown both in control (A) 
and in GLP-2 treated (B) specimens. The arrows indicated some myenteric neurons. Bar: A, B = 10 μm.
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contractile responses, enhances the amplitude of the 
NO-mediated fast relaxant responses and increases 
the nNOS expression in the nerve fibers. All of these 
effects of GLP-2 might contribute to gastric relaxation, 
thus increasing the organ capacity. Since gastric 
distension represents a peripheral satiety signal[30]  from 
a physiological point of view, it could be hypothesized 
that the relaxant effects of GLP-2 might contribute to 
suppress feeding behavior in rodents[31,32].
In conclusion, this study shows for the first time 
that GLP-2 influences the neurally-induced responses 
in gastric strips from mice through a modulatory action 
on the nitrergic neurotransmission and increases nNOS 
expression.
COMMENTS
Background
Glucagon-like peptide-2 (GLP-2) has been shown to relax gastric smooth 
muscle acting on myenteric neurons. However, to our knowledge, no data 
are present in the literature on the effects of GLP-2 on the neurally-induced 
gastric responses elicited by electrical stimulation in in vitro preparations. For 
the above reason, they presently investigated whether GLP-2 influences the 
neurally-induced contractile and relaxant responses in strips from the mouse 
gastric fundus. Moreover, since nitric oxide (NO) is considered one of the 
major NANC inhibitory neurotransmitters responsible for the proximal stomach 
relaxation, they also evaluated the effects of GLP-2 on both the nitrergic 
neurotransmission and the neuronal nitric oxide (nNOS) expression.  
Research frontiers
Previous studies have indicated that GLP-2 might contribute to suppress 
feeding behavior in rodents. Thus, the relaxant effects of GLP-2 on gastric 
preparations, leading to organ distension, might represent peripheral satiety 
signals.
 
Innovations and breakthroughs
This is the first study showing that GLP-2 is able to influence the neurally-
induced responses in gastric strips from mice through a modulatory action on 
nitrergic neurotransmission and to increase nNOS expression.      
Applications
The evidence that GLP-2 is able to induce gastric relaxation, through the 
modulation of the nitrergic neurotransmission, contributes to the knowledge of 
Figure 6  Neuronal nitric oxide synthase-immunoreactivity in control and glucagon-like peptide-2 treated specimens. In control (A) and glucagon-like 
peptide-2 (GLP-2) treated (D) specimens, neuronal nitric oxide synthase-immunoreactivity (nNOS-IR) (green) is present in the soma of some myenteric neurons and 
in several nerve fibers. DAPI fluorescent staining for DNA (blue) identified the nuclei of both smooth muscle and neural cells (B-E). In C and F, merged images of 
nNOS and Bisbenzimide Hoechst Trihydrochloride (BHT) fluorescent staining are shown. When the primary antibody is omitted (G), only the BHT labelling is observed 
(H). The quantitative analysis showed a significant increase (I) in nNOS-IR myenteric neurons (left side) and in IR fibers in the entire muscle coat (right side). aP < 0.05 
vs controls (unpaired Student's t-test). mp: Myenteric plexus; cml: Circular muscle layer; lml: Longitudinal muscle layer. Bar: A-H = 10 μm.
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its peripheral effects. The results highlight an additional site of action that might 
be implicated in the hormone control of feeding behavior.
Terminology
Gastric motor responses are the result of a balance between nervous excitatory, 
mainly cholinergic, and NANC inhibitory influences exerted on smooth 
muscle. During EFS, both excitatory and NANC inhibitory nervous fibers are 
simultaneously activated. The release of neurotransmitters from enteric neurons 
may be modulated by a variety of substances, including hormones. 
Peer-review
This is a very interesting study investigating the influence of GLP2 on neurally-
induced responses in gastric fundal strips.
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